BioAtla Secures $40 Million Funding to Advance Ozuriftamab Vedotin into Phase 3 Trial for Oropharyngeal Cancer
核心洞察
BioAtla announced a $40 million special purpose vehicle transaction with GATC Health to advance ozuriftamab vedotin (Oz-V (搜索)) into Phase 3 development for second-line oropharyngeal squamous cell carcinoma (搜索).
The company will receive an initial $5 million by January 2026 for general operations and clinical trial expenses, with the remaining $35 million expected to close in Q1 2026 when the registrational study begins.
BioAtla will retain 65% ownership of Oz-V (搜索) across all solid tumor indications while leading Phase 3 trial execution through data readout for potential accelerated approval.
BioAtla, Inc. announced a $40 million special purpose vehicle (SPV) transaction with GATC Health Corp (搜索). to advance ozuriftamab vedotin (Oz-V (搜索)) into Phase 3 development for second-line and beyond oropharyngeal squamous cell carcinoma (搜索) (OPSCC). The innovative financing structure allows BioAtla to retain majority ownership while securing critical funding for the registrational trial.
Financing Structure and Timeline
Under the SPV transaction, BioAtla will receive an initial $5 million for general operating and clinical trial expenses from Inversagen AI (搜索), LLC, a newly formed company with a mission to cure age-related diseases. The initial closing is expected to occur by January 30, 2026, with the remaining $35 million anticipated to close later in Q1 2026 when the Oz-V (搜索) registrational clinical study is expected to begin.
Inversagen AI (搜索) will receive an aggregate 35% ownership stake in Oz-V (搜索), while BioAtla will retain 65% ownership across all Oz-V solid tumor indications after completion of the transaction. BioAtla will lead Phase 3 trial execution for Oz-V in OPSCC through data readout for potential accelerated approval, with enrollment anticipated to begin early 2026.
"We are excited to announce this partnership for advancing Oz-V (搜索) into Phase 3 development for the treatment of patients with OPSCC under this creative, single-asset financing structure which maximizes our equity value for our shareholders," said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc.
ROR2 Target and Mechanism of Action
Oz-V (搜索) targets ROR2 (搜索), a transmembrane receptor tyrosine kinase that is present across many different solid tumors including head and neck, lung, cervical, triple-negative breast cancer (搜索), and melanoma (搜索). Overexpression of ROR2, a non-canonical wnt5A signaling receptor, forms a cancer axis that is associated with poor prognosis and resistance to chemo- and immunotherapies.
Ian Jenkins, Chief Scientific Officer at GATC Health, explained the therapeutic significance: "ROR2 (搜索) is an attractive therapeutic target as it functions at the crossroads of cancer, senescence, and inflammation. ROR2 not only drives tumor progression, but also regulates cellular senescence to modulate growth arrest, and influences inflammatory responses that together affect tissue homeostasis and aging."
Clinical Development and Regulatory Status
The Phase 3 stage clinical asset is targeting the treatment of OPSCC patients who have previously progressed on PD-1/L1 therapies with or without platinum chemotherapy. HPV associated expression of E6 and/or E7 oncoproteins drives cancer progression by upregulating ROR2 (搜索) expression, creating a clear therapeutic rationale.
The FDA has granted Fast Track Designation to Oz-V (搜索) for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (搜索) (SCCHN). Short noted that the company has "a clear registrational path with the potential for accelerated approval in the US."
Market Opportunity and Expansion Potential
There is potential to expand the application of Oz-V (搜索) more broadly beyond OPSCC to all HPV-positive cancers, which represents a market opportunity of over $7 billion worldwide. BioAtla continues to advance discussions with potential partners to expand the opportunity more broadly with Oz-V into HPV-positive solid tumors, including cervical cancer (搜索).
Disease Background
OPSCC is a subset of squamous cell carcinoma of the head and neck (搜索) (SCCHN) arising from the squamous cells that line the oropharynx, the middle part of the throat. A striking year-to-year increase in OPSCC is due to the rapidly increasing incidence of HPV infections which currently represents approximately 80% of OPSCC in the United States. The prognosis is currently poor for patients with recurrent/metastatic OPSCC who have previously received standard treatments including surgery, radiation, platinum-based chemotherapy, and PD-1 inhibitor therapy.
Technology Platform
The Conditionally Active Biologics (CAB) technology is a proprietary technology engineered to bind only in acidic, inflammatory conditions found in diseased microenvironments, but not in normal tissues. By targeting key surface markers like ROR2 (搜索), a receptor overexpressed in multiple solid tumors (pH5.3-6.7) and recognized for its role in inflamed senescent cells or Senescence Associated Secretory Phenotype (SASP; approximate pH6.5-7.0) regulation, CAB-enabled biologics enhance the precision approach to reduce chronic inflammation and tumor progression, while sparing beneficial cells.
Jayson Uffens, Chief Technology Officer at GATC Health, highlighted the platform's potential: "BioAtla's CAB platform offers a novel, highly specific approach to senolytic therapy with the potential to overcome major limitations of current strategies that often harm beneficial senescent cells. Enabling the selective removal of inflamed, pathogenic senescent cells positions us at the forefront of advances in the treatment of longevity and age-related disease."